A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis.
about
My treatment approach to rheumatoid arthritisEULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 updatePoor prognostic factors guiding treatment decisions in rheumatoid arthritis patients: a review of data from randomized clinical trials and cohort studies.The US7 score is sensitive to change in a large cohort of patients with rheumatoid arthritis over 12 months of therapy.Performance of matrices developed to identify patients with early rheumatoid arthritis with rapid radiographic progression despite methotrexate therapy: an external validation study based on the ESPOIR cohort data.Can Synovial Pathobiology Integrate with Current Clinical and Imaging Prediction Models to Achieve Personalized Health Care in Rheumatoid Arthritis?Anti-citrullinated peptide antibodies are the strongest predictor of clinically relevant radiographic progression in rheumatoid arthritis patients achieving remission or low disease activity: A post hoc analysis of a nationwide cohort in Japan.Relationship between time-integrated disease activity estimated by DAS28-CRP and radiographic progression of anatomical damage in patients with early rheumatoid arthritis.EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugsFeasibility of tailored treatment based on risk stratification in patients with early rheumatoid arthritis.Predicting the outcome of ankylosing spondylitis therapyLow- versus high-dose rituximab for rheumatoid arthritis: a systematic review and meta-analysis.Infliximab: 12 years of experienceBiologic-free remission of established rheumatoid arthritis after discontinuation of abatacept: a prospective, multicentre, observational study in Japan.Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial.Response to 'Feasibility of tailored treatment based on risk stratification in patients with early rheumatoid arthritis'.Current smoking status is a strong predictor of radiographic progression in early rheumatoid arthritis: results from the SWEFOT trial.Osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand as prognostic factors in rheumatoid arthritis: results from the ESPOIR cohort.Hyaluronan Inhibits Tlr-4-Dependent RANKL Expression in Human Rheumatoid Arthritis Synovial FibroblastsA profile of immune response to herpesvirus is associated with radiographic joint damage in rheumatoid arthritis.Baseline serum MMP-3 levels in patients with Rheumatoid Arthritis are still independently predictive of radiographic progression in a longitudinal observational cohort at 8 years follow upAssessment of synovitis to predict bone erosions in rheumatoid arthritis.Identifying patients with rheumatoid arthritis with moderate disease activity at risk of significant radiographic progression despite methotrexate treatment.The Scottish Early Rheumatoid Arthritis (SERA) Study: an inception cohort and biobankThe role of genetic variants in CRP in radiographic severity in African Americans with early and established rheumatoid arthritisRelationship of multi-biomarker disease activity score and other risk factors with radiographic progression in an observational study of patients with rheumatoid arthritis.Association of a multibiomarker disease activity score at multiple time-points with radiographic progression in rheumatoid arthritis: results from the SWEFOT trialPerformance of matrix-based risk models for rapid radiographic progression in a cohort of patients with established rheumatoid arthritis.Matrix to predict rapid radiographic progression of early rheumatoid arthritis patients from the community treated with methotrexate or leflunomide: results from the ESPOIR cohort.Prognostic Factors Toward Clinically Relevant Radiographic Progression in Patients With Rheumatoid Arthritis in Clinical Practice: A Japanese Multicenter, Prospective Longitudinal Cohort Study for Achieving a Treat-to-Target StrategyGoals for rheumatoid arthritis: treating to target or treating to prevent?Urinary interleukin-6 as a predictor of radiographic progression in rheumatoid arthritis: A 3-year evaluation.Immune response profiling in early rheumatoid arthritis: discovery of a novel interaction of treatment response with viral immunity.Recovery of clinical but not radiographic outcomes by the delayed addition of adalimumab to methotrexate-treated Japanese patients with early rheumatoid arthritis: 52-week results of the HOPEFUL-1 trial.RAPID and FAST4WARD trials: certolizumab pegol for rheumatoid arthritis.Predicting outcomes in rheumatoid arthritis.When to initiate and discontinue biologic treatments for rheumatoid arthritis?Risk estimation in rheumatoid arthritis: from bench to bedside.Clinical parameters and biomarkers for anti-TNF treatment prognosis in rheumatoid arthritis patients.Relationship between disease activity indices and their individual components and radiographic progression in RA: a systematic literature review.
P2860
Q26829955-7A53DD64-6F8B-4C8F-9A26-26931A35C4B2Q26859134-B1046586-971A-41B3-9D56-8C2D555A215AQ30235123-20C76202-6636-4D7C-9320-C2DBF2E81C69Q30453312-EEAB5CCF-FB6D-479C-9C13-3969BE26FA5AQ31104875-1A2754AD-5F33-42DE-88FB-810740E044E0Q33627758-3ED2DCFE-FC5A-42E8-99F9-95EE0B36D5E5Q33688001-C34FA3BD-8DD5-4EBA-8EC7-55AAA8E9EA4CQ33915665-DDCB51A9-54BC-4F33-AE74-DC21D28DB607Q34110066-802EB47C-2946-4FF5-A09F-2CF98C191133Q34374946-2ADABDE0-97B9-4BC6-9FC3-2936B7A41B37Q34905433-C70BAB61-A68B-4D1B-8F3E-C5932364EAEDQ34975404-E0CB261F-DC46-4292-B5AD-09880DFDE318Q35070446-1B7560F5-547F-4968-ACE1-7A063987CBABQ35214632-6BEF23CB-6CBB-4A61-AC83-A4E073EA2FE9Q35605424-464481D2-ECAE-4626-AAAC-A73AB9C54F5FQ35762424-E04A18C0-BCFD-4E1A-9AE4-C1AE61DA1E92Q35891851-17D18E75-F980-4BFE-8856-F203F8E78A93Q35899487-DF8E84FA-9145-45D8-836A-576A2606F94DQ35982598-4E446F98-AFC7-4165-81D9-EB3687F12085Q36084979-6D5C1EAF-A96B-4AD5-88C1-C925CECBA653Q36085007-95DA0F31-E098-4641-9CC9-06D3F1B89A6CQ36111299-FD43E1E5-5698-4438-995C-E1234A98FC42Q36183760-288E7F4C-B8EA-496F-926F-B4DFD6D6C85DQ36187856-A3953279-3120-4EB3-BE07-7FE68BA57770Q36447420-DC790328-EC9F-4D95-9C31-DB4D227F93D2Q36456822-2B2F9F68-A7B3-490C-A04D-CF8D3CC414C1Q36657901-5AC9527C-9503-4688-9D65-5E04F41F5C34Q36674075-725D63FD-3C62-4048-86FB-EE1C71D58221Q36907694-3DE8AFB5-5B40-41A0-8262-64CF511B7FE0Q37206416-B739023B-E774-4613-BE83-90AAC8E675C2Q37301156-B9DD12DA-261C-4AB6-B2E5-559CAE149155Q37330396-3849F97F-3F9F-4C3A-8463-40213D87872BQ37689761-D2092922-B7B6-4CF4-85B2-2B4414438651Q37706297-F566F2B1-96BB-44CF-B4D0-B83D405C066EQ37786625-F4BC4841-8C6E-4DAB-ADEA-873BBEE90E4BQ37825802-9187CA15-D3D1-4838-BC0E-362B12C151C7Q37831972-5294D7D6-9C48-4C4C-BFAC-0568647CCACFQ38182346-19ACC54C-7A32-45F3-80A2-8BA71830AB52Q38236144-3DAA6E5F-2D50-47DB-863F-02B510A087DCQ38270519-EAFCAC7F-1B71-48C6-A3F0-0EEB95DD64F6
P2860
A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 09 July 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A pilot risk model for the pre ...... ssion in rheumatoid arthritis.
@en
A pilot risk model for the pre ...... ssion in rheumatoid arthritis.
@nl
type
label
A pilot risk model for the pre ...... ssion in rheumatoid arthritis.
@en
A pilot risk model for the pre ...... ssion in rheumatoid arthritis.
@nl
prefLabel
A pilot risk model for the pre ...... ssion in rheumatoid arthritis.
@en
A pilot risk model for the pre ...... ssion in rheumatoid arthritis.
@nl
P2093
P2860
P356
P1433
P1476
A pilot risk model for the pre ...... ssion in rheumatoid arthritis.
@en
P2093
Daniel Aletaha
E William St Clair
Nathan Vastesaeger
Stephen Xu
P2860
P304
P356
10.1093/RHEUMATOLOGY/KEP155
P577
2009-07-09T00:00:00Z